Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients
Evidence of relative effectiveness of local treatments for hepatocellular carcinoma (HCC) is scanty. We investigated, in a retrospective cohort study, whether surgical resection, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), and transarterial embolization with (TACE) or withou...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/564706 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562010782433280 |
|---|---|
| author | Simona Signoriello Annalisa Annunziata Nicola Lama Giuseppe Signoriello Paolo Chiodini Ilario De Sio Bruno Daniele Giovanni G. Di Costanzo Fulvio Calise Graziano Olivieri Vincenzo Castaldo Rosario Lanzetta Guido Piai Giampiero Marone Mario Visconti Mario Fusco Massimo Di Maio Francesco Perrone Ciro Gallo Giovanni B. Gaeta |
| author_facet | Simona Signoriello Annalisa Annunziata Nicola Lama Giuseppe Signoriello Paolo Chiodini Ilario De Sio Bruno Daniele Giovanni G. Di Costanzo Fulvio Calise Graziano Olivieri Vincenzo Castaldo Rosario Lanzetta Guido Piai Giampiero Marone Mario Visconti Mario Fusco Massimo Di Maio Francesco Perrone Ciro Gallo Giovanni B. Gaeta |
| author_sort | Simona Signoriello |
| collection | DOAJ |
| description | Evidence of relative effectiveness of local treatments for hepatocellular carcinoma (HCC) is scanty. We investigated, in a retrospective cohort study, whether surgical resection, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), and transarterial embolization with (TACE) or without (TAE) chemotherapy resulted in different survival in clinical practice. All patients first diagnosed with HCC and treated with any locoregional therapy from 1998 to 2002 in twelve Italian hospitals were eligible. Overall survival (OS) was the unique endpoint. Three main comparisons were planned: RFA versus PEI, surgical resection versus RFA/PEI (combined), TACE/TAE versus RFA/PEI (combined). Propensity score method was used to minimize bias related to non random treatment assignment. Overall 425 subjects were analyzed, with 385 (91%) deaths after a median followup of 7.7 years. OS did not significantly differ between RFA and PEI (HR 1.11, 95% CI 0.79–1.57), between surgery and RFA/PEI (HR 0.95, 95% CI 0.64–1.41) and between TACE/TAE and RFA/PEI (HR 0.88, 95% CI 0.66–1.17). 5-year OS probabilities were 0.14 for RFA, 0.18 for PEI, 0.27 for surgery, and 0.15 for TACE/TAE. No locoregional treatment for HCC was found to be more effective than the comparator. Adequately powered randomized clinical trials are still needed to definitely assess relative effectiveness of locoregional HCC treatment. |
| format | Article |
| id | doaj-art-d3a2e6e4ec4d4aae813574e88adeed08 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-d3a2e6e4ec4d4aae813574e88adeed082025-02-03T01:23:45ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/564706564706Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World PatientsSimona Signoriello0Annalisa Annunziata1Nicola Lama2Giuseppe Signoriello3Paolo Chiodini4Ilario De Sio5Bruno Daniele6Giovanni G. Di Costanzo7Fulvio Calise8Graziano Olivieri9Vincenzo Castaldo10Rosario Lanzetta11Guido Piai12Giampiero Marone13Mario Visconti14Mario Fusco15Massimo Di Maio16Francesco Perrone17Ciro Gallo18Giovanni B. Gaeta19Department of Medicine and Public Health, Second University of Napoli, Via L. Armanni 5, 80138 Napoli, ItalyDepartment of Medicine and Public Health, Second University of Napoli, Via L. Armanni 5, 80138 Napoli, ItalyDepartment of Medicine and Public Health, Second University of Napoli, Via L. Armanni 5, 80138 Napoli, ItalyDepartment of Medicine and Public Health, Second University of Napoli, Via L. Armanni 5, 80138 Napoli, ItalyDepartment of Medicine and Public Health, Second University of Napoli, Via L. Armanni 5, 80138 Napoli, ItalyDepartment of Clinical and Experimental Medicine and Surgery “F. Magrassi-A. Lanzara”, Second University of Napoli, Via S. Pansini 5, 80131 Napoli, ItalyRummo Hospital, Via dell'Angelo 1, 82100 Benevento, ItalyCardarelli Hospital, Via A. Cardarelli 9, 80131 Napoli, ItalyCardarelli Hospital, Via A. Cardarelli 9, 80131 Napoli, ItalyNational Cancer Institute, Via Mariano Semmola, 80131 Napoli, ItalyMoscati Hospital, Città Ospedaliera, Contrada Amoretta, 83100 Avellino, ItalyRummo Hospital, Via dell'Angelo 1, 82100 Benevento, ItalyS. Anna and S. Sebastiano Hospital, Via F. Palasciano, 81100 Caserta, ItalyAscalesi Hospital, Via Egiziaca a Forcella, 31 80139 Napoli, ItalyIncurabili Hospital, Via Maria Longo 50, 80138 Napoli, ItalyCampania Cancer Registry, Azienda Sanitaria Locale Napoli 3 sud, Piazza San Giovanni, 80031 Brusciano (NA), ItalyNational Cancer Institute, Via Mariano Semmola, 80131 Napoli, ItalyNational Cancer Institute, Via Mariano Semmola, 80131 Napoli, ItalyDepartment of Medicine and Public Health, Second University of Napoli, Via L. Armanni 5, 80138 Napoli, ItalyDepartment of Clinical and Experimental Medicine and Surgery “F. Magrassi-A. Lanzara”, Second University of Napoli, Via S. Pansini 5, 80131 Napoli, ItalyEvidence of relative effectiveness of local treatments for hepatocellular carcinoma (HCC) is scanty. We investigated, in a retrospective cohort study, whether surgical resection, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), and transarterial embolization with (TACE) or without (TAE) chemotherapy resulted in different survival in clinical practice. All patients first diagnosed with HCC and treated with any locoregional therapy from 1998 to 2002 in twelve Italian hospitals were eligible. Overall survival (OS) was the unique endpoint. Three main comparisons were planned: RFA versus PEI, surgical resection versus RFA/PEI (combined), TACE/TAE versus RFA/PEI (combined). Propensity score method was used to minimize bias related to non random treatment assignment. Overall 425 subjects were analyzed, with 385 (91%) deaths after a median followup of 7.7 years. OS did not significantly differ between RFA and PEI (HR 1.11, 95% CI 0.79–1.57), between surgery and RFA/PEI (HR 0.95, 95% CI 0.64–1.41) and between TACE/TAE and RFA/PEI (HR 0.88, 95% CI 0.66–1.17). 5-year OS probabilities were 0.14 for RFA, 0.18 for PEI, 0.27 for surgery, and 0.15 for TACE/TAE. No locoregional treatment for HCC was found to be more effective than the comparator. Adequately powered randomized clinical trials are still needed to definitely assess relative effectiveness of locoregional HCC treatment.http://dx.doi.org/10.1100/2012/564706 |
| spellingShingle | Simona Signoriello Annalisa Annunziata Nicola Lama Giuseppe Signoriello Paolo Chiodini Ilario De Sio Bruno Daniele Giovanni G. Di Costanzo Fulvio Calise Graziano Olivieri Vincenzo Castaldo Rosario Lanzetta Guido Piai Giampiero Marone Mario Visconti Mario Fusco Massimo Di Maio Francesco Perrone Ciro Gallo Giovanni B. Gaeta Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients The Scientific World Journal |
| title | Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients |
| title_full | Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients |
| title_fullStr | Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients |
| title_full_unstemmed | Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients |
| title_short | Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients |
| title_sort | survival after locoregional treatments for hepatocellular carcinoma a cohort study in real world patients |
| url | http://dx.doi.org/10.1100/2012/564706 |
| work_keys_str_mv | AT simonasignoriello survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT annalisaannunziata survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT nicolalama survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT giuseppesignoriello survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT paolochiodini survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT ilariodesio survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT brunodaniele survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT giovannigdicostanzo survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT fulviocalise survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT grazianoolivieri survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT vincenzocastaldo survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT rosariolanzetta survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT guidopiai survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT giampieromarone survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT mariovisconti survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT mariofusco survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT massimodimaio survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT francescoperrone survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT cirogallo survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients AT giovannibgaeta survivalafterlocoregionaltreatmentsforhepatocellularcarcinomaacohortstudyinrealworldpatients |